{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:53:23Z","timestamp":1788951203402,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000024","name":"the Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["106665"],"award-info":[{"award-number":["106665"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s11010-017-2943-y","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T14:57:13Z","timestamp":1488380233000},"page":"151-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol"],"prefix":"10.1007","volume":"429","author":[{"given":"Zaid H.","family":"Maayah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan N.","family":"Althurwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"El-Sherbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Abdelhamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno G.","family":"Siraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman O. S.","family":"El-Kadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"2943_CR1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1067\/mhj.2001.113218","volume":"141","author":"BA Vakili","year":"2001","unstructured":"Vakili BA, Okin PM, Devereux RB (2001) Prognostic implications of left ventricular hypertrophy. Am Heart J 141:334\u2013341. doi: 10.1067\/mhj.2001.113218","journal-title":"Am Heart J"},{"key":"2943_CR2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1157\/13087900","volume":"59","author":"JE Carreno","year":"2006","unstructured":"Carreno JE, Apablaza F, Ocaranza MP, Jalil JE (2006) Cardiac hypertrophy: molecular and cellular events. Rev Esp Cardiol 59:473\u2013486","journal-title":"Rev Esp Cardiol"},{"key":"2943_CR3","doi-asserted-by":"publisher","first-page":"H8","DOI":"10.1152\/ajpheart.01303.2004","volume":"289","author":"K Berenji","year":"2005","unstructured":"Berenji K, Drazner MH, Rothermel BA, Hill JA (2005) Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 289:H8\u2013H16. doi: 10.1152\/ajpheart.01303.2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2943_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa020265","volume":"347","author":"D Levy","year":"2002","unstructured":"Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347:1397\u20131402. doi: 10.1056\/NEJMoa020265","journal-title":"N Engl J Med"},{"key":"2943_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1152\/physrev.00021.2001","volume":"82","author":"RJ Roman","year":"2002","unstructured":"Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131\u2013185. doi: 10.1152\/physrev.00021.2001","journal-title":"Physiol Rev"},{"key":"2943_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.pharmthera.2009.12.002","volume":"125","author":"BN Zordoky","year":"2010","unstructured":"Zordoky BN, El-Kadi AO (2010) Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 125:446\u2013463. doi: 10.1016\/j.pharmthera.2009.12.002","journal-title":"Pharmacol Ther"},{"key":"2943_CR7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2174\/1389200211314060007","volume":"14","author":"OH Elshenawy","year":"2013","unstructured":"Elshenawy OH, Anwar-Mohamed A, El-Kadi AO (2013) 20-Hydroxyeicosatetraenoic acid is a potential therapeutic target in cardiovascular diseases. Curr Drug Metab 14:706\u2013719","journal-title":"Curr Drug Metab"},{"key":"2943_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.vph.2012.12.002","volume":"58","author":"OH Elshenawy","year":"2013","unstructured":"Elshenawy OH, Anwar-Mohamed A, Abdelhamid G, El-Kadi AO (2013) Murine atrial HL-1 cell line is a reliable model to study drug metabolizing enzymes in the heart. Vascul Pharmacol 58:326\u2013333. doi: 10.1016\/j.vph.2012.12.002","journal-title":"Vascul Pharmacol"},{"key":"2943_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/03602530600632063","volume":"38","author":"HM Korashy","year":"2006","unstructured":"Korashy HM, El-Kadi AO (2006) The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases. Drug Metab Rev 38:411\u2013450. doi: 10.1080\/03602530600632063","journal-title":"Drug Metab Rev"},{"key":"2943_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.prostaglandins.2011.12.003","volume":"98","author":"KU Malik","year":"2012","unstructured":"Malik KU, Jennings BL, Yaghini FA, Sahan-Firat S, Song CY, Estes AM, Fang XR (2012) Contribution of cytochrome P450 1B1 to hypertension and associated pathophysiology: a novel target for antihypertensive agents. Prostaglandins Other Lipid Mediat 98:69\u201374. doi: 10.1016\/j.prostaglandins.2011.12.003","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2943_CR11","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1096\/fj.02-0138com","volume":"16","author":"T Thum","year":"2002","unstructured":"Thum T, Borlak J (2002) Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16:1537\u20131549. doi: 10.1096\/fj.02-0138com","journal-title":"FASEB J"},{"key":"2943_CR12","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1124\/dmd.108.023077","volume":"36","author":"BN Zordoky","year":"2008","unstructured":"Zordoky BN, Aboutabl ME, El-Kadi AO (2008) Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. Drug Metab Dispos 36:2277\u20132286. doi: 10.1124\/dmd.108.023077","journal-title":"Drug Metab Dispos"},{"key":"2943_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1161\/HYPERTENSIONAHA.111.183301","volume":"59","author":"BL Jennings","year":"2012","unstructured":"Jennings BL, Anderson LJ, Estes AM, Yaghini FA, Fang XR, Porter J, Gonzalez FJ, Campbell WB, Malik KU (2012) Cytochrome P450 1B1 contributes to renal dysfunction and damage caused by angiotensin II in mice. Hypertension 59:348\u2013354. doi: 10.1161\/HYPERTENSIONAHA.111.183301","journal-title":"Hypertension"},{"key":"2943_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.bcp.2013.11.015","volume":"87","author":"AA El-Sherbeni","year":"2014","unstructured":"El-Sherbeni AA, El-Kadi AO (2014) Alterations in cytochrome P450-derived arachidonic acid metabolism during pressure overload-induced cardiac hypertrophy. Biochem Pharmacol 87:456\u2013466. doi: 10.1016\/j.bcp.2013.11.015","journal-title":"Biochem Pharmacol"},{"key":"2943_CR15","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1161\/HYPERTENSIONAHA.112.202606","volume":"60","author":"BL Jennings","year":"2012","unstructured":"Jennings BL, Estes AM, Anderson LJ, Fang XR, Yaghini FA, Fan Z, Gonzalez FJ, Campbell WB, Malik KU (2012) Cytochrome P450 1B1 gene disruption minimizes deoxycorticosterone acetate-salt-induced hypertension and associated cardiac dysfunction and renal damage in mice. Hypertension 60:1510\u20131516. doi: 10.1161\/HYPERTENSIONAHA.112.202606","journal-title":"Hypertension"},{"key":"2943_CR16","first-page":"207","volume":"29","author":"ET Morgan","year":"2001","unstructured":"Morgan ET (2001) Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 29:207\u2013212","journal-title":"Drug Metab Dispos"},{"key":"2943_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00204-015-1620-8","volume":"90","author":"ZH Maayah","year":"2016","unstructured":"Maayah ZH, El-Kadi AO (2016) The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy. Arch Toxicol 90:119\u2013136. doi: 10.1007\/s00204-015-1620-8","journal-title":"Arch Toxicol"},{"key":"2943_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/cvr\/cvn346","volume":"82","author":"CM Jenkins","year":"2009","unstructured":"Jenkins CM, Cedars A, Gross RW (2009) Eicosanoid signalling pathways in the heart. Cardiovasc Res 82:240\u2013249. doi: 10.1093\/cvr\/cvn346","journal-title":"Cardiovasc Res"},{"key":"2943_CR19","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1172\/JCI5897","volume":"103","author":"T Cyrus","year":"1999","unstructured":"Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD (1999) Disruption of the 12\/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 103:1597\u20131604. doi: 10.1172\/JCI5897","journal-title":"J Clin Invest"},{"key":"2943_CR20","first-page":"H1774","volume":"259","author":"K Nozawa","year":"1990","unstructured":"Nozawa K, Tuck ML, Golub M, Eggena P, Nadler JL, Stern N (1990) Inhibition of lipoxygenase pathway reduces blood pressure in renovascular hypertensive rats. Am J Physiol 259:H1774\u2013H1780","journal-title":"Am J Physiol"},{"key":"2943_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-014-1419-z","author":"ZH Maayah","year":"2015","unstructured":"Maayah ZH, El-Kadi AO (2015) 5-, 12- and 15-Hydroxyeicosatetraenoic acids induce cellular hypertrophy in the human ventricular cardiomyocyte, RL-14 cell line, through MAPK- and NF-kappaB-dependent mechanism. Arch Toxicol. doi: 10.1007\/s00204-014-1419-z","journal-title":"Arch Toxicol"},{"key":"2943_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-015-1620-8","author":"ZH Maayah","year":"2015","unstructured":"Maayah ZH, El-Kadi AO (2015) The role of mid-chain hydroxyeicosatetraenoic acids in the pathogenesis of hypertension and cardiac hypertrophy. Arch Toxicol. doi: 10.1007\/s00204-015-1620-8","journal-title":"Arch Toxicol"},{"key":"2943_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-015-9308-7","author":"ZH Maayah","year":"2015","unstructured":"Maayah ZH, Abdelhamid G, El-Kadi AO (2015) Development of cellular hypertrophy by 8-hydroxyeicosatetraenoic acid in the human ventricular cardiomyocyte, RL-14 cell line, is implicated by MAPK and NF-kappaB. Cell Biol Toxicol. doi: 10.1007\/s10565-015-9308-7","journal-title":"Cell Biol Toxicol"},{"key":"2943_CR24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/01.RES.62.4.687","volume":"62","author":"KE Burhop","year":"1988","unstructured":"Burhop KE, Selig WM, Malik AB (1988) Monohydroxyeicosatetraenoic acids (5-HETE and 15-HETE) induce pulmonary vasoconstriction and edema. Circ Res 62:687\u2013698","journal-title":"Circ Res"},{"key":"2943_CR25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1050-1738(03)00027-6","volume":"13","author":"Y Wen","year":"2003","unstructured":"Wen Y, Gu J, Peng X, Zhang G, Nadler J (2003) Overexpression of 12-lipoxygenase and cardiac fibroblast hypertrophy. Trends Cardiovasc Med 13:129\u2013136","journal-title":"Trends Cardiovasc Med"},{"key":"2943_CR26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/01.RES.88.1.70","volume":"88","author":"Y Wen","year":"2001","unstructured":"Wen Y, Gu J, Liu Y, Wang PH, Sun Y, Nadler JL (2001) Overexpression of 12-lipoxygenase causes cardiac fibroblast cell growth. Circ Res 88:70\u201376","journal-title":"Circ Res"},{"key":"2943_CR27","doi-asserted-by":"crossref","first-page":"29055","DOI":"10.1016\/S0021-9258(19)62012-0","volume":"269","author":"G Wallukat","year":"1994","unstructured":"Wallukat G, Morwinski R, Kuhn H (1994) Modulation of the beta-adrenergic response of cardiomyocytes by specific lipoxygenase products involves their incorporation into phosphatidylinositol and activation of protein kinase C. J Biol Chem 269:29055\u201329060","journal-title":"J Biol Chem"},{"key":"2943_CR28","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1084\/jem.20082596","volume":"206","author":"Y Kayama","year":"2009","unstructured":"Kayama Y, Minamino T, Toko H, Sakamoto M, Shimizu I, Takahashi H, Okada S, Tateno K, Moriya J, Yokoyama M, Nojima A, Yoshimura M, Egashira K, Aburatani H, Komuro I (2009) Cardiac 12\/15 lipoxygenase-induced inflammation is involved in heart failure. J Exp Med 206:1565\u20131574. doi: 10.1084\/jem.20082596","journal-title":"J Exp Med"},{"key":"2943_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1152\/physiolgenomics.90297.2008","volume":"41","author":"A Molojavyi","year":"2010","unstructured":"Molojavyi A, Lindecke A, Raupach A, Moellendorf S, Kohrer K, Godecke A (2010) Myoglobin-deficient mice activate a distinct cardiac gene expression program in response to isoproterenol-induced hypertrophy. Physiol Genomics 41:137\u2013145. doi: 10.1152\/physiolgenomics.90297.2008","journal-title":"Physiol Genomics"},{"key":"2943_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10741-007-9007-4","volume":"12","author":"OE Osadchii","year":"2007","unstructured":"Osadchii OE (2007) Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 12:66\u201386. doi: 10.1007\/s10741-007-9007-4","journal-title":"Heart Fail Rev"},{"key":"2943_CR31","first-page":"289","volume":"41","author":"J Meszaros","year":"1990","unstructured":"Meszaros J, Levai G (1990) Ultrastructural and electrophysiological alterations during the development of catecholamine-induced cardiac hypertrophy and failure. Acta Biol Hung 41:289\u2013307","journal-title":"Acta Biol Hung"},{"key":"2943_CR32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0008-6363(98)00076-5","volume":"39","author":"SA Doggrell","year":"1998","unstructured":"Doggrell SA, Brown L (1998) Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 39:89\u2013105","journal-title":"Cardiovasc Res"},{"key":"2943_CR33","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1253\/circj.69.987","volume":"69","author":"N Oyama","year":"2005","unstructured":"Oyama N, Urasawa K, Kaneta S, Sakai H, Saito T, Takagi C, Yoshida I, Kitabatake A, Tsutsui H (2005) Chronic beta-adrenergic receptor stimulation enhances the expression of G-Protein coupled receptor kinases, GRK2 and GRK5, in both the heart and peripheral lymphocytes. Circ J 69:987\u2013990","journal-title":"Circ J"},{"key":"2943_CR34","first-page":"8164","volume":"61","author":"YJ Chun","year":"2001","unstructured":"Chun YJ, Kim S, Kim D, Lee SK, Guengerich FP (2001) A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res 61:8164\u20138170","journal-title":"Cancer Res"},{"key":"2943_CR35","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1124\/dmd.114.057836","volume":"42","author":"AA El-Sherbeni","year":"2014","unstructured":"El-Sherbeni AA, El-Kadi AO (2014) Characterization of arachidonic acid metabolism by rat cytochrome P450 enzymes: the involvement of CYP1As. Drug Metab Dispos 42:1498\u20131507. doi: 10.1124\/dmd.114.057836","journal-title":"Drug Metab Dispos"},{"key":"2943_CR36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1471-4159.1997.69020581.x","volume":"69","author":"Y Liu","year":"1997","unstructured":"Liu Y, Peterson DA, Kimura H, Schubert D (1997) Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 69:581\u2013593","journal-title":"J Neurochem"},{"key":"2943_CR37","volume-title":"Molecular Cloning. A Laboratory Manual","author":"J Sambrook","year":"1989","unstructured":"Sambrook J, Fritsch EF and Maniatatis T (1989) In: Ford, N. (Ed.), Molecular Cloning. A Laboratory Manual. Cold Spring Harbour Laboratory Press, Plainview."},{"key":"2943_CR38","unstructured":"Davidson MM (2007) Immortalization of human post-mitotic cells. Google Patents"},{"key":"2943_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2014.11.005","author":"ZH Maayah","year":"2014","unstructured":"Maayah ZH, Elshenawy OH, Althurwi HN, Abdelhamid G, El-Kadi AO (2014) Human fetal ventricular cardiomyocyte, RL-14 cell line, is a promising model to study drug metabolizing enzymes and their associated arachidonic acid metabolites. J Pharmacol Toxicol Methods. doi: 10.1016\/j.vascn.2014.11.005","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2943_CR40","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00204-012-0996-y","volume":"87","author":"ZH Maayah","year":"2013","unstructured":"Maayah ZH, El Gendy MA, El-Kadi AO, Korashy HM (2013) Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation. Arch Toxicol 87:847\u2013856. doi: 10.1007\/s00204-012-0996-y","journal-title":"Arch Toxicol"},{"key":"2943_CR41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00204-013-1159-5","volume":"88","author":"ZH Maayah","year":"2014","unstructured":"Maayah ZH, Ansari MA, El Gendy MA, Al-Arifi MN, Korashy HM (2014) Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway. Arch Toxicol 88:725\u2013738. doi: 10.1007\/s00204-013-1159-5","journal-title":"Arch Toxicol"},{"key":"2943_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402\u2013408. doi: 10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"2943_CR43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.vph.2013.02.004","volume":"58","author":"MM Tse","year":"2013","unstructured":"Tse MM, Aboutabl ME, Althurwi HN, Elshenawy OH, Abdelhamid G, El-Kadi AO (2013) Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line. Vascul Pharmacol 58:363\u2013373. doi: 10.1016\/j.vph.2013.02.004","journal-title":"Vascul Pharmacol"},{"key":"2943_CR44","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/nar\/19.9.2499","volume":"19","author":"NC Andrews","year":"1991","unstructured":"Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499","journal-title":"Nucleic Acids Res"},{"key":"2943_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ijc.25054","volume":"127","author":"N Bhattacharya","year":"2010","unstructured":"Bhattacharya N, Sarno A, Idler IS, Fuhrer M, Zenz T, Dohner H, Stilgenbauer S, Mertens D (2010) High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay. Int J Cancer 127:404\u2013411. doi: 10.1002\/ijc.25054","journal-title":"Int J Cancer"},{"key":"2943_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.taap.2009.09.012","volume":"242","author":"BN Zordoky","year":"2010","unstructured":"Zordoky BN, Anwar-Mohamed A, Aboutabl ME, El-Kadi AO (2010) Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol 242:38\u201346. doi: 10.1016\/j.taap.2009.09.012","journal-title":"Toxicol Appl Pharmacol"},{"key":"2943_CR47","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1124\/dmd.115.063776","volume":"43","author":"HN Althurwi","year":"2015","unstructured":"Althurwi HN, Maayah ZH, Elshenawy OH, El-Kadi AO (2015) Early changes in cytochrome P450s and their associated arachidonic acid metabolites play a crucial role in the initiation of cardiac hypertrophy induced by isoproterenol. Drug Metab Dispos 43:1254\u20131266. doi: 10.1124\/dmd.115.063776","journal-title":"Drug Metab Dispos"},{"key":"2943_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10557-014-6510-4","volume":"28","author":"BL Jennings","year":"2014","unstructured":"Jennings BL, Montanez DE, May ME Jr, Estes AM, Fang XR, Yaghini FA, Kanu A, Malik KU (2014) Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats. Cardiovasc Drugs Ther 28:145\u2013161. doi: 10.1007\/s10557-014-6510-4","journal-title":"Cardiovasc Drugs Ther"},{"key":"2943_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.12.016","author":"ZH Maayah","year":"2016","unstructured":"Maayah ZH, Althurwi HN, Abdelhamid G, Lesyk G, Jurasz P, El-Kadi AO (2016) CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism. Pharmacol Res. doi: 10.1016\/j.phrs.2015.12.016","journal-title":"Pharmacol Res"},{"key":"2943_CR50","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1194\/jlr.M600212-JLR200","volume":"47","author":"D Nieves","year":"2006","unstructured":"Nieves D, Moreno JJ (2006) Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3T6 fibroblast growth. J Lipid Res 47:2681\u20132689. doi: 10.1194\/jlr.M600212-JLR200","journal-title":"J Lipid Res"},{"key":"2943_CR51","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.biocel.2008.02.020","volume":"40","author":"SP Barry","year":"2008","unstructured":"Barry SP, Davidson SM, Townsend PA (2008) Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40:2023\u20132039. doi: 10.1016\/j.biocel.2008.02.020","journal-title":"Int J Biochem Cell Biol"},{"key":"2943_CR52","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1172\/JCI11093","volume":"106","author":"D Fatkin","year":"2000","unstructured":"Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, Schoen FJ, Giewat M, Seidman CE, Seidman JG (2000) An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 106:1351\u20131359. doi: 10.1172\/JCI11093","journal-title":"J Clin Invest"},{"key":"2943_CR53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.physiol.62.1.321","volume":"62","author":"H Kiriazis","year":"2000","unstructured":"Kiriazis H, Kranias EG (2000) Genetically engineered models with alterations in cardiac membrane calcium-handling proteins. Annu Rev Physiol 62:321\u2013351. doi: 10.1146\/annurev.physiol.62.1.321","journal-title":"Annu Rev Physiol"},{"key":"2943_CR54","doi-asserted-by":"publisher","first-page":"H869","DOI":"10.1152\/ajpheart.00452.2010","volume":"300","author":"MR Locher","year":"2011","unstructured":"Locher MR, Razumova MV, Stelzer JE, Norman HS, Moss RL (2011) Effects of low-level \u03b1-myosin heavy chain expression on contractile kinetics in porcine myocardium. Am J Physiol Heart Circ Physiol 300:H869\u2013H878. doi: 10.1152\/ajpheart.00452.2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2943_CR55","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0140-6736(03)13976-1","volume":"362","author":"JA Lemos de","year":"2003","unstructured":"de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. The Lancet 362:316\u2013322. doi: 10.1016\/S0140-6736(03)13976-1","journal-title":"The Lancet"},{"key":"2943_CR56","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1054\/jcaf.2002.0805288","volume":"8","author":"R Latini","year":"2002","unstructured":"Latini R, Masson S, de Angelis N, Anand I (2002) Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. J Card Fail 8:288\u2013299","journal-title":"J Card Fail"},{"key":"2943_CR57","doi-asserted-by":"publisher","first-page":"e92903","DOI":"10.1371\/journal.pone.0092903","volume":"9","author":"EJ Cox","year":"2014","unstructured":"Cox EJ, Marsh SA (2014) A systematic review of fetal genes as biomarkers of cardiac hypertrophy in rodent models of diabetes. PLoS One 9:e92903. doi: 10.1371\/journal.pone.0092903","journal-title":"PLoS One"},{"key":"2943_CR58","doi-asserted-by":"publisher","first-page":"H1891","DOI":"10.1152\/ajpheart.00655.2010","volume":"299","author":"S Sahan-Firat","year":"2010","unstructured":"Sahan-Firat S, Jennings BL, Yaghini FA, Song CY, Estes AM, Fang XR, Farjana N, Khan AI, Malik KU (2010) 2,3\u2032,4,5\u2032-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1. Am J Physiol Heart Circ Physiol 299:H1891\u2013H1901. doi: 10.1152\/ajpheart.00655.2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2943_CR59","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/j.1476-5381.2009.00461.x","volume":"158","author":"ME Aboutabl","year":"2009","unstructured":"Aboutabl ME, Zordoky BN, El-Kadi AO (2009) 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 158:1808\u20131819. doi: 10.1111\/j.1476-5381.2009.00461.x","journal-title":"Br J Pharmacol"},{"key":"2943_CR60","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.tiv.2009.12.002","volume":"24","author":"BN Zordoky","year":"2010","unstructured":"Zordoky BN, El-Kadi AO (2010) 2,3,7,8-Tetrachlorodibenzo-p-dioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism. Toxicol In Vitro 24:863\u2013871. doi: 10.1016\/j.tiv.2009.12.002","journal-title":"Toxicol In Vitro"},{"key":"2943_CR61","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1124\/dmd.32.8.840","volume":"32","author":"D Choudhary","year":"2004","unstructured":"Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB (2004) Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32:840\u2013847","journal-title":"Drug Metab Dispos"},{"key":"2943_CR62","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/mol.59.3.646","volume":"59","author":"S Wassmann","year":"2001","unstructured":"Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M, Nickenig G (2001) Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59:646\u2013654","journal-title":"Mol Pharmacol"},{"key":"2943_CR63","doi-asserted-by":"crossref","first-page":"19323","DOI":"10.1074\/jbc.274.27.19323","volume":"274","author":"Z Xie","year":"1999","unstructured":"Xie Z, Kometiani P, Liu J, Li J, Shapiro JI, Askari A (1999) Intracellular reactive oxygen species mediate the linkage of Na+\/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes. J Biol Chem 274:19323\u201319328","journal-title":"J Biol Chem"},{"key":"2943_CR64","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1161\/01.CIR.98.8.794","volume":"98","author":"K Nakamura","year":"1998","unstructured":"Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M (1998) Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98:794\u2013799","journal-title":"Circulation"},{"key":"2943_CR65","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0735-1097(00)01123-2","volume":"37","author":"K Tanaka","year":"2001","unstructured":"Tanaka K, Honda M, Takabatake T (2001) Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 37:676\u2013685","journal-title":"J Am Coll Cardiol"},{"key":"2943_CR66","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12012-008-9027-x","volume":"8","author":"PG Kopf","year":"2008","unstructured":"Kopf PG, Huwe JK, Walker MK (2008) Hypertension, cardiac hypertrophy, and impaired vascular relaxation induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are associated with increased superoxide. Cardiovasc Toxicol 8:181\u2013193. doi: 10.1007\/s12012-008-9027-x","journal-title":"Cardiovasc Toxicol"},{"key":"2943_CR67","first-page":"173","volume":"8","author":"W Zhang","year":"2003","unstructured":"Zhang W, Elimban V, Nijjar MS, Gupta SK, Dhalla NS (2003) Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure. Exp. Clin Cardiol 8:173\u2013183","journal-title":"Clin Cardiol"},{"key":"2943_CR68","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1210\/edrv.22.2.0428","volume":"22","author":"G Pearson","year":"2001","unstructured":"Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22:153\u2013183. doi: 10.1210\/edrv.22.2.0428","journal-title":"Endocr Rev"},{"key":"2943_CR69","doi-asserted-by":"publisher","first-page":"18733","DOI":"10.1073\/pnas.0609158103","volume":"103","author":"D Xu","year":"2006","unstructured":"Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, Davis BB, Low R, Hammock BD, Chiamvimonvat N (2006) Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103:18733\u201318738. doi: 10.1073\/pnas.0609158103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2943_CR70","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11033-007-9112-4","volume":"35","author":"EM Li S","year":"2008","unstructured":"Li S EM, Yu B (2008) Adriamycin induces myocardium apoptosis through activation of nuclear factor kappaB in rat. Mol Biol Rep 35:489\u2013494. doi: 10.1007\/s11033-007-9112-4","journal-title":"Mol Biol Rep"},{"key":"2943_CR71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/hc0102.101365","volume":"105","author":"G Esposito","year":"2002","unstructured":"Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105:85\u201392","journal-title":"Circulation"},{"key":"2943_CR72","doi-asserted-by":"publisher","first-page":"14074","DOI":"10.1073\/pnas.0610906104","volume":"104","author":"NH Purcell","year":"2007","unstructured":"Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J, Molkentin JD (2007) Genetic inhibition of cardiac ERK1\/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A 104:14074\u201314079. doi: 10.1073\/pnas.0610906104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2943_CR73","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1046\/j.1523-1747.2002.19611.x","volume":"119","author":"J Chen","year":"2002","unstructured":"Chen J, Hoffman BB, Isseroff RR (2002) Beta-adrenergic receptor activation inhibits keratinocyte migration via a cyclic adenosine monophosphate-independent mechanism. J Invest Dermatol 119:1261\u20131268. doi: 10.1046\/j.1523-1747.2002.19611.x","journal-title":"J Invest Dermatol"},{"key":"2943_CR74","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00210-003-0849-6","volume":"369","author":"TH Cheng","year":"2004","unstructured":"Cheng TH, Liu JC, Lin H, Shih NL, Chen YL, Huang MT, Chan P, Cheng CF, Chen JJ (2004) Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy. Naunyn Schmiedebergs Arch Pharmacol 369:239\u2013244. doi: 10.1007\/s00210-003-0849-6","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2943_CR75","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.cardiores.2005.04.030","volume":"67","author":"S Kawano","year":"2005","unstructured":"Kawano S, Kubota T, Monden Y, Kawamura N, Tsutsui H, Takeshita A, Sunagawa K (2005) Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc Res 67:689\u2013698. doi: 10.1016\/j.cardiores.2005.04.030","journal-title":"Cardiovasc Res"},{"key":"2943_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.5376","author":"X Hu","year":"2015","unstructured":"Hu X, Wang H, Lv X, Chu L, Liu Z, Wei X, Chen Q, Zhu L, Cui W (2015) Cardioprotective effects of tannic acid on isoproterenol-induced myocardial injury in rats: further insight into \u2018French Paradox\u2019. Phytother Res. doi: 10.1002\/ptr.5376","journal-title":"Phytother Res"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-017-2943-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11010-017-2943-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-017-2943-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:38:24Z","timestamp":1658709504000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11010-017-2943-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":76,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2943"],"URL":"https:\/\/doi.org\/10.1007\/s11010-017-2943-y","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}